For InvestorsAntares Pharma: Making Medicines Feel Better

Recent News

Information contained in these press releases should be considered accurate only as of the date it was prepared. Information may change over time. Do not assume that the information remains accurate at a later date. Antares Pharma, Inc. is not obligated to update the press releases and information contained in this section of the Company’s website.

22 Oct 2020
Antares Pharma to Report Third Quarter 2020 Finanical and Operating Results

01 Oct 2020
Antares Pharma Enters Exclusive License Agreement with Ferring Pharmaceuticals For Nocdurna® In U.S.

08 Sep 2020
Antares Pharma to Present at the H.C. Wainwright 22nd Annual Global Virtual Investment Conference

10 Aug 2020
Antares Pharma Appoints Tram Bui As Vice President of Corporate Communications and Investor Relations

06 Aug 2020
Antares Pharma Reports Strong Second Quarter 2020 Operating and Financial Results; Reinstates Full-Year 2020 Revenue Guidance

03 Aug 2020
Antares Pharma and Lunatus Enter Into An Exclusive Distribution Agreement for XYOSTED® In Saudi Arabia And The United Arab Emirates

30 Jul 2020
Antares Pharma to Report Second Quarter 2020 Operating and Finanical Results

21 Jul 2020
First Commerical Product Using Antares Pharma's Multi-Dose Pen Platform Launches in Europe

20 Jul 2020
Antares Pharma Appoints Patrick Shea Senior Vice President of Commerical

11 Jun 2020
Antares Pharma to Present at the Raymond James Human Health Innovation Conference

27 May 2020
Antares Pharma to Present at the Jefferies Virtual Healthcare Conference

05 May 2020
Antares Pharma Reports Frist Quarter 2020 Operating and Financial Results

28 Apr 2020
Antares Pharma to Report First Quarter 2020 Operating and Finanical Results

03 Mar 2020
Antares Pharma Reports Fourth Quarter And Full Year 2019 Operating and Financial Results

26 Feb 2020
Antares Pharma To Present At The Cowen And Company 40th Annual Health Care Conference

25 Feb 2020
Antares Pharma To Report Fourth Quarter And Full Year 2019 Financial And Operating Results

27 Jan 2020
Antares Pharma Announces Full-Year 2020 Net Revenue Guidance Range of $135 to $155 Million

For Investors

Press Release Archive



Sign up for breaking news on ATRS

* indicates required